MYX Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$4.38 |
52 Week High | AU$7.46 |
52 Week Low | AU$2.75 |
Beta | 1.27 |
11 Month Change | -3.95% |
3 Month Change | -36.80% |
1 Year Change | -7.59% |
33 Year Change | -31.56% |
5 Year Change | -56.63% |
Change since IPO | -63.50% |
Recent News & Updates
Recent updates
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 06Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
Dec 03Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Dec 01Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
Apr 12Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 01We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
Nov 16Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Nov 10Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
May 17Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Mar 22How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?
Mar 01What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition
Feb 08Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit
Jan 18Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares
Dec 27Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?
Dec 09A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation
Nov 24Shareholder Returns
MYX | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -7.4% | -1.4% | -2.2% |
1Y | -7.6% | 63.4% | 5.4% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned 63.4% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 5.4% over the past year.
Price Volatility
MYX volatility | |
---|---|
MYX Average Weekly Movement | 6.6% |
Pharmaceuticals Industry Average Movement | 10.3% |
Market Average Movement | 8.1% |
10% most volatile stocks in AU Market | 16.4% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: MYX's share price has been volatile over the past 3 months.
Volatility Over Time: MYX's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
MYX fundamental statistics | |
---|---|
Market cap | AU$355.43m |
Earnings (TTM) | -AU$274.18m |
Revenue (TTM) | AU$319.28m |
1.1x
P/S Ratio-1.3x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MYX income statement (TTM) | |
---|---|
Revenue | AU$319.28m |
Cost of Revenue | AU$145.07m |
Gross Profit | AU$174.21m |
Other Expenses | AU$448.39m |
Earnings | -AU$274.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -3.38 |
Gross Margin | 54.56% |
Net Profit Margin | -85.87% |
Debt/Equity Ratio | 5.5% |
How did MYX perform over the long term?
See historical performance and comparison